



Drug-eluting stents will
solve the problem! Pro:

Konstantinos Katsanos

Department of Radiology
Patras University Hospital
Rion, Greece

Head: Prof. D. Siablis

Disclosure



I have the following potential conflicts of interest:

- Consulting
- Employment in industry
- Stockholder of a healthcare company
- Owner of a healthcare company
- Honoraria (Cordis, JNJ)*
- I do not have any potential conflict of interest

What's the problem?

- **170million diabetics worldwide (x2 by 2030)**
- **15% suffer from diabetic foot ulcers**
- **~30-50% lack suitable autogenous vein**
- **1-year angiographic re-obstruction after angioplasty ± bare stents: 41-66%**


Siablis D et al. J Endovasc Ther 2007;14:241–250

Feiring AJ et al. JACC 2004;44(12):2307-14

Rand T et al. CVIR 2006;29(1):29-38

Brem H et al. J. Clin. Invest. 2007;117:1219–1222

Infrapopliteal angioplasty



Romiti M, et al. Meta-analysis of infrapopliteal angioplasty. *J Vasc Surg.* 2008

Infrapopliteal DES?

BUILDING
ENDOVASCULAR
SYNERGIES

MEET 2008
MULTIDISCIPLINARY EUROPEAN
ENDOVASCULAR THERAPY
www.meetcongress.com



Gorilla fibroid embolization, SIR 2007, US

BTK DES: published data



Sirolimus-eluting stents (CYPHER)
2 controlled trials and 2 single-arm studies

Paclitaxel-eluting stents (TAXUS)
1 single-arm cohort study

Single-center series and registries...

Multivariate analysis sirolimus vs. bare stents



Binary Logistic Regression Analysis


Dependent Variable	Independent Variable*	Odds Ratio (95% Confidence Intervals)	p
6 Months			
Primary patency	Stent type†	5.625 (1.711–18.493)	0.004
In-stent binary restenosis	Stent type†	0.067 (0.021–0.217)	<0.001
In-segment binary restenosis	Stent type†	0.229 (0.099–0.533)	0.001
TLR	Stent type†	0.057 (0.008–0.426)	0.005
1 Year			
Primary patency	Stent type†	10.401 (3.425–31.589)	<0.001
In-stent binary restenosis	Stent type†	0.156 (0.060–0.407)	<0.001
In-segment binary restenosis	Stent type†	0.089 (0.023–0.349)	0.001
TLR	Stent type†	0.238 (0.067–0.841)	0.026

TLR: target lesion reintervention.

* Significant at 0.05 level.

† Bare metal or sirolimus-eluting.

SES vs BMS long-term results




*Siablis D, Karnabatidis D, Katsanos K, et al.
Double-arm controlled study / Cox proportional regression analysis*

Angiographic results


Cox proportional hazards regression analysis



Primary patency




In-stent restenosis




Clinical results

Mortality



Limb salvage






Re-intervention free survival

Cox proportional hazards regression analysis

Clinically-driven re-interventions




Siablis D, Karnabatidis D, Katsanos K, et al. Patras, Greece

CLI Patient Survival

BUILDING
ENDOVASCULAR
SYNERGIES

MEET 2008
MULTIDISCIPLINARY EUROPEAN
ENDOVASCULAR THERAPY
www.meetcongress.com



¹Siablis D, Karnabatidis D, Katsanos K, unpublished data


²Romiti M, et al. Meta-analysis of infrapopliteal angioplasty. *J Vasc Surg.* 2008

³Albers M, et al. Meta-analysis of infrapopliteal vein bypass grafts. *J Vasc Surg.* 2005

⁴Kandarpa K et al. Peripheral transcatheter interventions. *J Vasc Interv Radiol.* 2001

⁵TASC II Working Group. Intersociety consensus. *J Vasc Surg.* 2007

CLI limb Salvage



¹Siablis D, Karnabatidis D, Katsanos K, unpublished data

²Romiti M, et al. Meta-analysis of infrapopliteal angioplasty. J Vasc Surg. 2008


³Albers M, et al. Meta-analysis of infrapopliteal vein bypass grafts. J Vasc Surg. 2005

⁴Kandarpa K et al. Peripheral transcatheter interventions. J Vasc Interv Radiol. 2001

⁵TASC II Working Group. Intersociety consensus. J Vasc Surg. 2007

Re-intervention free survival

BUILDING
ENDOVASCULAR
SYNERGIES




¹Siablis D, Karnabatidis D, Katsanos K, unpublished data

²Albers M, et al. Meta-analysis of infrapopliteal vein bypass grafts. J Vasc Med Biol. 2008

³Romiti M, et al. Meta-analysis of infrapopliteal angioplasty. J Vasc Surg. 2008

The -olimus era



Sirolimus

Zotarolimus

Biolimus

Everolimus

Supralimus

Novolimus

Pimecrolimus

etc-olimus

Thank you

BUILDING
ENDOVASCULAR
SYNERGIES

MEET 2008
MULTIDISCIPLINARY EUROPEAN
ENDOVASCULAR THERAPY

www.meetcongress.com

